Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)

Chonbuk National University Hospital100 enrolled

Overview

This study will validate the impact of comprehensive geriatric assessments using activity of daily living (ADL), instrumental activity of daily living (IADL), and Charlson's comorbidity index (CCI) on survival and toxicities in Korean patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Lymphoma, Large B-cell, Diffuse

Eligibility

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with newly diagnosed CD20+ DLBCL * 65 years old or over * Scheduled to receive R-CHOP chemotherapy * Informed consent Exclusion Criteria: * Other histology than CD20+ DLBCL * Primary central nervous system DLBCL * Patients with a diagnosis of cancer (other than basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, well differentiated thyroid cancer \[papillary or follicular thyroid cancer\]) within 3 years before the study entry or with any treatment for cancer within 3 years before entry * Consent withdrawal

Locations (2)

Chonnam National University Hwasun Hospital

Hwasun, South Korea

Chonbuk National University Hospital

Jeonju, South Korea

Outcomes

Primary Outcomes

Event-free survival

Event-free survival was defined as death, relapse from complete remission, progression during or after treatment, and discontinuation or changes of therapy during treatments

Time frame: 2 years

Secondary Outcomes

Overall survival

Time frame: 5 years

Progression-free survival

Time frame: 5 years

Cumulative incidence of grade 3/4 adverse events and premature treatment discontinuation

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.